Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD334-005 extension study in moderate to severe active ulcerative colitis
MOH_2017-04-27_000358Phase 2Recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in autoimmune colitis (3 arms), sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Long-term safety and tolerability of APD334. Started Dec 2015; status: recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-04-27_000358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-27_000358.